Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Normal neutrophil myosin IIA localization in an immunofluorescence analysis can rule out MYH9 disorders.

Kitamura K, Yoshida K, Shiraishi Y, Chiba K, Tanaka H, Furukawa K, Miyano S, Ogawa S, Kunishima S.

J Thromb Haemost. 2013 Nov;11(11):2071-3. doi: 10.1111/jth.12406. No abstract available.

2.

Myosin IIA is critical for organelle distribution and F-actin organization in megakaryocytes and platelets.

Pertuy F, Eckly A, Weber J, Proamer F, Rinckel JY, Lanza F, Gachet C, Léon C.

Blood. 2014 Feb 20;123(8):1261-9. doi: 10.1182/blood-2013-06-508168.

3.

Somatic mosaicism in MYH9 disorders: the need to carefully evaluate apparently healthy parents.

Kunishima S, Kitamura K, Matsumoto T, Sekine T, Saito H.

Br J Haematol. 2014 Jun;165(6):885-7. doi: 10.1111/bjh.12797. No abstract available.

PMID:
24611568
4.

Establishment of mouse model of MYH9 disorders: heterozygous R702C mutation provokes macrothrombocytopenia with leukocyte inclusion bodies, renal glomerulosclerosis and hearing disability.

Suzuki N, Kunishima S, Ikejiri M, Maruyama S, Sone M, Takagi A, Ikawa M, Okabe M, Kojima T, Saito H, Naoe T, Matsushita T.

PLoS One. 2013 Aug 20;8(8):e71187. doi: 10.1371/journal.pone.0071187.

5.

Beware of hidden trains: simultaneous discovery of a MYH9-related disease and chronic lymphocytic leukaemia.

Chaquin M, Marzac C, Legrand O, Favier R.

Br J Haematol. 2014 Jan;164(2):162. doi: 10.1111/bjh.12583. No abstract available.

PMID:
24117195
6.

MYH9-related disease: a novel prognostic model to predict the clinical evolution of the disease based on genotype-phenotype correlations.

Pecci A, Klersy C, Gresele P, Lee KJ, De Rocco D, Bozzi V, Russo G, Heller PG, Loffredo G, Ballmaier M, Fabris F, Beggiato E, Kahr WH, Pujol-Moix N, Platokouki H, Van Geet C, Noris P, Yerram P, Hermans C, Gerber B, Economou M, De Groot M, Zieger B, De Candia E, Fraticelli V, Kersseboom R, Piccoli GB, Zimmermann S, Fierro T, Glembotsky AC, Vianello F, Zaninetti C, Nicchia E, Güthner C, Baronci C, Seri M, Knight PJ, Balduini CL, Savoia A.

Hum Mutat. 2014 Feb;35(2):236-47. doi: 10.1002/humu.22476.

PMID:
24186861
7.

Immunofluorescence analysis of neutrophil nonmuscle myosin heavy chain-A in MYH9 disorders: association of subcellular localization with MYH9 mutations.

Kunishima S, Matsushita T, Kojima T, Sako M, Kimura F, Jo EK, Inoue C, Kamiya T, Saito H.

Lab Invest. 2003 Jan;83(1):115-22.

PMID:
12533692
8.

The first two cases of MYH9 disorders in Thailand: an international collaborative study.

Sirachainan N, Komwilaisak P, Kitamura K, Hongeng S, Sekine T, Kunishima S.

Ann Hematol. 2015 Apr;94(4):707-9. doi: 10.1007/s00277-014-2234-6. No abstract available.

PMID:
25394719
9.
10.

Delayed diagnosis of MYH-9–related disorder and the role of light microscopy in congenital macrothrombocytopenias.

Perez Botero J, Patnaik MM.

Blood. 2016 Apr 14;127(15):1940. No abstract available.

PMID:
27540618
11.

PRBC-derived plasma induces non-muscle myosin type IIA-mediated neutrophil migration and morphologic change.

Yu C, Xu L, Chen LF, Guan YJ, Kim M, Biffl WL, Chin YE.

Immunopharmacol Immunotoxicol. 2013 Feb;35(1):71-9. doi: 10.3109/08923973.2012.677046.

12.

Successful renal transplantation in MYH9-related disorder with severe macrothrombocytopenia: first report in Korea.

Min SY, Ahn HJ, Park WS, Kim JW.

Transplant Proc. 2014;46(2):654-6. doi: 10.1016/j.transproceed.2013.11.144.

PMID:
24656038
13.

Non-muscle myosin heavy chain IIA and IIB interact and co-localize in living cells: relevance for MYH9-related disease.

Marini M, Bruschi M, Pecci A, Romagnoli R, Musante L, Candiano G, Ghiggeri GM, Balduini C, Seri M, Ravazzolo R.

Int J Mol Med. 2006 May;17(5):729-36.

PMID:
16596254
14.

Successful immunostaining demonstrates abnormal intracytoplasmic MYH9 protein (NMMHC-IIA) in neutrophils of a dog with May-Hegglin anomaly.

Flatland B, Kunishima S.

Vet Clin Pathol. 2011 Dec;40(4):409-10. doi: 10.1111/j.1939-165X.2011.00378.x. No abstract available.

PMID:
22136472
15.

Analysis of clinical manifestations, mutant gene and encoded protein in two Chinese MYH9-related disease families.

Yi Y, Sen Zhang G, Xu M, San Ling Z, Ru Shao X, Zeng Li J, Ma J.

Clin Chim Acta. 2006 Nov;373(1-2):49-54.

PMID:
16806139
16.

Clinical, pathological, and genetic analysis of ten patients with MYH9-related disease.

Sun XH, Wang ZY, Yang HY, Cao LJ, Su J, Yu ZQ, Bai X, Ruan CG.

Acta Haematol. 2013;129(2):106-13. doi: 10.1159/000342123.

PMID:
23207509
17.

[Hereditary sensorineural hearing impairment and macrothrombocytopenia: a rare MYH9 gene mutation].

Böttcher A, Knecht R, Busch CJ, Lörincz BB, Dalchow CV.

HNO. 2013 Feb;61(2):159-60, 162-5. doi: 10.1007/s00106-012-2521-2. German.

PMID:
23223919
18.

Misdiagnosed MYH9 related inherited macrothrombocytopenia with an inadvertent splenectomy.

Thakral B, Rojanapremsuk T, Saluja K, Eldibany M.

Pathology. 2015 Jun;47(4):377-9. doi: 10.1097/PAT.0000000000000254. No abstract available.

PMID:
25938358
19.

Rod mutations associated with MYH9-related disorders disrupt nonmuscle myosin-IIA assembly.

Franke JD, Dong F, Rickoll WL, Kelley MJ, Kiehart DP.

Blood. 2005 Jan 1;105(1):161-9.

20.

Phosphorylation of the myosin IIA tailpiece regulates single myosin IIA molecule association with lytic granules to promote NK-cell cytotoxicity.

Sanborn KB, Mace EM, Rak GD, Difeo A, Martignetti JA, Pecci A, Bussel JB, Favier R, Orange JS.

Blood. 2011 Nov 24;118(22):5862-71. doi: 10.1182/blood-2011-03-344846.

Supplemental Content

Support Center